Home › Funds › Privium Fund Management B.V. › FATE
Privium Fund Management B.V. position in FATE
FATE THERAPEUTICS INC · Health Care
Privium Fund Management B.V. reported holding 414,311 shares of FATE (FATE THERAPEUTICS INC) in its Q3 2026 13F filing — a position valued at US$982K, representing 0.19% of its reported portfolio and ranking #40 among its reported holdings. Privium Fund Management B.V. has disclosed FATE holdings in 9 of the last 9 reported quarters, going back to Q3 2024.
Last updated: 2026-11-13 · Source: SEC EDGAR Form 13F-HR
How Privium Fund Management B.V.'s FATE position evolved
Privium Fund Management B.V. first disclosed a stake in FATE in Q3 2024 at 50,000 shares (US$175K). The position peaked in Q2 2026 at 414,311 shares, worth US$1.1M. Across 9 filings, Privium Fund Management B.V. increased the stake 6 time(s), trimmed it 0 time(s) and left it unchanged 2 time(s). The most recent filing (Q3 2026) shows 414,311 shares valued at US$982K. Notable position changes include a 74% increase in Q4 2024 (shares fell 52% over the following quarter), a 25% increase in Q1 2025 (shares rose 42% over the following quarter), a 200% increase in Q3 2025 (shares fell 22% over the following quarter).
Quarter by quarter
| Quarter | Shares | Value | Change |
|---|---|---|---|
| Q3 2024 | 50.00K | $175.00K | New |
| Q4 2024 | 87.00K | $143.55K | Add |
| Q1 2025 | 109.03K | $86.14K | Add |
| Q2 2025 | 111.09K | $126.64K | Add |
| Q3 2025 | 333.22K | $419.86K | Add |
| Q4 2025 | 369.10K | $362.68K | Add |
| Q1 2026 | 414.31K | $497.17K | Add |
| Q2 2026 | 414.31K | $1.12M | Hold |
| Q3 2026 | 414.31K | $981.92K | Hold |
Dots on the line are colored by change type; missing quarters mean no position was reported.
About FATE and 13F data
FATE (FATE THERAPEUTICS INC) is a Health Care company. 19 other funds we track also report a position in FATE — the largest reported positions include Redmile Group, LLC (US$34.8M), JOHNSON & JOHNSON (US$8.0M), Bruce & Co., Inc. (US$2.7M). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.
Other funds holding FATE
- Redmile Group, LLC 12.87M sh · $34.76M · Q2 2026
- JOHNSON & JOHNSON 3.38M sh · $8.01M · Q3 2026
- Bruce & Co., Inc. 989.19K sh · $2.67M · Q2 2026
More on Privium Fund Management B.V.
FAQ
How long has Privium Fund Management B.V. held FATE?
Privium Fund Management B.V. has disclosed FATE holdings in 9 of the last 9 reported quarters, going back to Q3 2024.
What is Privium Fund Management B.V.'s current position in FATE?
As of Q3 2026, Privium Fund Management B.V. holds 414.31K shares of FATE (FATE THERAPEUTICS INC), valued at $981.92K, representing 0.19% of its reported portfolio and ranking #40.
Has Privium Fund Management B.V. been buying or selling FATE?
In the latest 13F filing (Q3 2026), Privium Fund Management B.V. held unchanged its position in FATE. The position peaked in Q2 2026 at 414.31K shares.
Which other funds hold FATE?
Other major institutional holders of FATE include Redmile Group, LLC, JOHNSON & JOHNSON, Bruce & Co., Inc., among 19 funds with disclosed positions.
Where does this data come from?
All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.